On July 24, 2025, Acting Director of the USPTO, Coke Morgan Stewart, denied institution of inter partes review in IPR2025-00601 and IPR2025-00602, but referred the petition in IPR2025-00603 to the Board in Amgen Inc. v. Bristol-Myers Squibb Co. The Bristol-Myers Squibb (“BMS”) patents, challenged by Petitioner Amgen, relate to methods of…
